Global Antimicrobial Susceptibility Testing Market Industry Size, Share, Analysis, Trend & Future Planning 2022
Bharat Book Bureau Provides the Trending Market Research Report on“Global Antimicrobial Susceptibility Testing Market Forecast to 2022” underLife Sciences category. The report provides information on industry overview, market size, latest developments, industry trends, Keyplayers, global presence, and their future prospects.
Antimicrobial Susceptibility Testing Market projected to grow at aCAGR of 5.1% during the forecast period
The global antimicrobial susceptibility testing market is projected to reachUSD 3.47 billion by 2022 from USD 2.71 billion in 2017, at a CAGR of 5.1%. The major factors driving the growth of the market include the rising prevalence of infectious diseases; emergence of multidrug-resistance due to drug abuse; and increasing funds, research grants, and public-private investments. However, the high cost of automated antimicrobial susceptibility testing systems and unfavorable reimbursement scenario are restraining the growth of this market.
The automated antimicrobial susceptibility testing segment is expected to grow at the highest rate during the forecast period
On the basis of product, the global antimicrobial susceptibility testing market is segmented automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. The automated laboratory instruments segment is estimated to witness the highest growth during the forecast period, primarily due to on-going technological advancements and increasing demand for faster susceptibility testing systems.
Request a free sample copy ofAntimicrobial Susceptibility TestingMarket Report @ https://www.bharatbook.com/request-sample/992658
The disk diffusion segment accounted for the largest share of antimicrobial susceptibility testing market by method
On the basis of method, the antimicrobial susceptibility testing market is segmented into disk diffusion, dilution, ETEST, automated antimicrobial susceptibility testing, and genotypic methods. The disk diffusion segment is expected to have the largest share of the market in 2017. This is mainly attributed to factors such as its low cost and flexible nature.
The APAC market is expected to grow at the highest CAGR during the forecast period
Geographically, the antimicrobial susceptibility testing market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World. The APAC market is expected to register the highest growth rate during the forecast period. The fast growth of this segment is mainly due to the region’s large population and its mix of growing and developed economies, such as Japan, China, and India. Moreover, as markets in developed countries are increasingly becoming saturated, manufacturers and suppliers of antimicrobial susceptibility testing products are shifting their focus towards the Asian market, thereby driving the growth of this market during the forecast period.
Breakdown of supply-side primary interviews:
- By Company Type - Tier 1 – 25%, Tier 2 – 30% and Tier 3 – 45%
- By Designation - C-level – 26%, Director level – 30%, Others – 44%
- By Region - North America - 34%, Europe – 26%, APAC – 23%, RoW – 17%
The major players in the market included are bioMérieux (France), BD (US), Danaher (US), Thermo Fisher (US), and Bio-Rad (US).
To browse full research report with TOC, click the link below :
https://www.bharatbook.com/medical-devices-market-research-reports-992658/antimicrobial-susceptibility-testing-product-method-type-application-end-user-global-forecast.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email:poonam@bharatbook.com
Website:www.bharatbook.com
Follow us on: Twitter, Facebook, LinkedIn, Google Plus
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
